How to follow-up a patient who received tocilizumab in severe COVID-19: a case report

How to follow-up a patient who received tocilizumab in severe COVID-19: a case report

Abstract Background COVID-19 is characterized by fast deterioration in the mechanism of cytokine storm. Therefore, treatment with immunomodulating agents should be initiated as soon as hyperinflammation is established. Evidence for the use of tocilizumab (TCZ) in COVID-19 is emerging, but the drug i...

Full description

Bibliographic Details
Main Authors: Regina B. Podlasin, Justyna D. Kowalska, Andrzej Pihowicz, Beata Wojtycha-Kwaśnica, Magdalena Thompson, Tomasz Dyda, Hanna Czeszko-Paprocka, Andrzej Horban
Format: Article
Language:English
Published: BMC 2020-08-01
Series:European Journal of Medical Research
Subjects:
SARS-CoV-2
COVID-19
Tocilizumab
Chloroquine
ARDS
Cytokine storm
Online Access:http://link.springer.com/article/10.1186/s40001-020-00438-x

Internet

http://link.springer.com/article/10.1186/s40001-020-00438-x

Similar Items